Ramm Pharma Corp.’s Acquisition Of 49% Interest in Canapar Corp.

Ramm Pharma investe in Canapar rilevandone il 49%
Ambrogio Visconti
Tagged:

Cassels Brock & Blackwell and Grimaldi Studio Legale have represented Ramm Pharma in the transaction.Ramm Pharma Corp., a leader in plant-derived cannabinoid (CBD) pharmaceutical and other…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Ambrogio Visconti

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here